Zhang, Z.; Li, C.; Liao, W.; Huang, Y.; Wang, Z.
A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic Body Radiation Therapy versus Sorafenib and TACE in Advanced Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombus. Cancers 2022, 14, 3619.
https://doi.org/10.3390/cancers14153619
AMA Style
Zhang Z, Li C, Liao W, Huang Y, Wang Z.
A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic Body Radiation Therapy versus Sorafenib and TACE in Advanced Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombus. Cancers. 2022; 14(15):3619.
https://doi.org/10.3390/cancers14153619
Chicago/Turabian Style
Zhang, Zeyu, Chan Li, Weijun Liao, Yun Huang, and Zhiming Wang.
2022. "A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic Body Radiation Therapy versus Sorafenib and TACE in Advanced Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombus" Cancers 14, no. 15: 3619.
https://doi.org/10.3390/cancers14153619
APA Style
Zhang, Z., Li, C., Liao, W., Huang, Y., & Wang, Z.
(2022). A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic Body Radiation Therapy versus Sorafenib and TACE in Advanced Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombus. Cancers, 14(15), 3619.
https://doi.org/10.3390/cancers14153619
